A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Duvelisib (Primary) ; Rituximab
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms DYNAMO+R
- Sponsors Infinity Pharmaceuticals; Verastem
- 13 Apr 2017 This trial has been completed in Denmark (End date:2017-03-03) and discontinued in Belgium, according to European Clinical Trials Database.
- 10 Apr 2017 Status changed from active, no longer recruiting to discontinued.
- 04 Apr 2017 This trial has been discontinued in Austria (End date:2017-03-03) as per European Clinical Trials Database record.